The U.S. Food and Drug Administration has approved Seattle Genetics’ Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin’s lymphoma in newly diagnosed patients. This approval makes this the diseases' first new treatment in more than 40 years
The Adcetris combo replaces a chemotherapy drug that has been tied to potentially fatal lung toxicity.
Adcetris currently holds approval in the United States to treat other forms of blood cancer as well as patients with Hodgkin’s lymphoma who have already received a stem cell transplant or two chemotherapy treatments.
Read the full Reuters report